Should the risk of acquired immunodeficiency syndrome deter hepatitis B vaccination? A decision analysis.
The current epidemic of acquired immunodeficiency syndrome (AIDS) and fear that its causative agent contaminates the currently available hepatitis B vaccine may have deterred vaccine use. We formulated a decision-analytic model that compares the risk of death from hepatitis B and AIDS in those vaccinated with the risk of death from hepatitis B alone in those who wait two years for a synthetic vaccine. For individuals with 5% annual risk of hepatitis B, the best current estimate is that vaccination now would save 25 lives per 100,000. The best current estimate of the rate of vaccine-induced AIDS is zero, and one can be 95% confident that the rate is less than eight per 100,000. The rate would have to be considerably higher before postponement of vaccination would be rational for those for whom vaccination has been recommended.
D000163:Acquired Immunodeficiency Syndrome / Q000401:mortality / Q000635:transmission*; D006509:Hepatitis B / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D012306:Risk; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000009:adverse effects*
D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines